LGND PEER ANALYSIS

Ligand Pharmaceuticals Incorporated — metric-by-metric comparison with peers and the industry median

LGNDLigand Pharmaceuticals Incorporated

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

LGNDIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	LGND	TLX	CSL	MSB	Ind. Median
P/E	41.36	—	29.96●	—	18.06
P/B	6.37	6.38	2.24●	—	3.62
EV/EBITDA	27.11	120.20	10.35●	—	15.13
P/S	23.14	3.24	2.66●	31.30	10.65

Financial Health
Metric	LGND	TLX	CSL	MSB	Ind. Median
Current Ratio	21.28●	1.43	2.57	—	5.90
Debt/Equity	45.3%●	112.3%	67.4%	—	10.9%
NetDebt/EBITDA	-1.47●	13.13	2.22	—	1.15

Profitability
Metric	LGND	TLX	CSL	MSB	Ind. Median
Net Margin	55.9%●	-0.9%	9.2%	-115.3%	-125.7%
ROE	17.1%●	-1.8%	7.7%	-11.3%	-47.5%
ROA	12.6%●	-0.7%	3.8%	-8.6%	-35.8%
EBITDA Margin	81.0%●	3.0%	32.8%	-76.6%	-105.8%

Growth + Dividend
Metric	LGND	TLX	CSL	MSB	Ind. Median
Rev. Growth	51.2%	56.3%	4.8%	410.4%●	5.1%
NI Growth	—	—	-39.4%	—	12.1%
Div. Yield	—	—	2.5%●	0.0%	0.2%
Payout	—	—	103.1%	0.0%	0.0%

Valuation
Metric	LGND	ACLX	CELC	PTCT	SRRK	ERAS	Ind. Median
P/E	41.36	-28.30●	—	—	—	—	18.06
P/B	6.37	16.10	117.75	-40.79●	26.08	14.20	3.62
EV/EBITDA	27.11	-30.94●	—	—	—	—	15.13
P/S	23.14	290.72	40,924.92	8.90●	—	—	10.65

Financial Health
Metric	LGND	ACLX	CELC	PTCT	SRRK	ERAS	Ind. Median
Current Ratio	21.28●	4.44	12.31	2.44	8.64	9.52	5.90
Debt/Equity	45.3%	23.9%	365.4%	-218.9%●	74.5%	11.7%	10.9%
NetDebt/EBITDA	-1.47●	1.79	-0.29	12.52	0.69	0.73	1.15

Profitability
Metric	LGND	ACLX	CELC	PTCT	SRRK	ERAS	Ind. Median
Net Margin	55.9%●	-1,027.3%	-125,250.6%	-22.6%	—	—	-125.7%
ROE	17.1%●	-53.4%	-275.2%	—	-138.9%	-69.9%	-47.5%
ROA	12.6%●	-34.8%	-61.4%	-6.8%	-86.7%	-59.4%	-35.8%
EBITDA Margin	81.0%●	-888.3%	-112,116.2%	-14.5%	—	—	-105.8%

Growth + Dividend
Metric	LGND	ACLX	CELC	PTCT	SRRK	ERAS	Ind. Median
Rev. Growth	51.2%●	-79.4%	26.9%	-53.3%	—	-100.0%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on LGND

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.